Discovery and structure activity relationship study of novel indazole amide inhibitors for extracellular signal-regulated kinase1/2 (ERK1/2).

[1]  D. Uehling,et al.  Recent progress on MAP kinase pathway inhibitors. , 2015, Bioorganic & medicinal chemistry letters.

[2]  R. Jain,et al.  Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase. , 2015, Bioorganic & medicinal chemistry letters.

[3]  M. Lindvall,et al.  Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase. , 2015, Bioorganic & medicinal chemistry letters.

[4]  S. Knapp,et al.  A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics , 2014, Nature chemical biology.

[5]  J. Blake,et al.  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2. , 2014, Bioorganic & medicinal chemistry letters.

[6]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[7]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[8]  G. Bemis,et al.  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. , 2009, Journal of medicinal chemistry.

[9]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[10]  Xiaoling Xie,et al.  Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.

[11]  E. Nishida,et al.  ERK MAP kinase in G1 cell cycle progression and cancer , 2006, Cancer science.